Mesenchymal Stem/Stromal Cells Derived from Cervical Cancer Promote M2 Macrophage Polarization
Víctor Adrián Cortés-Morales,
Luis Chávez-Sánchez,
Leticia Rocha-Zavaleta,
Sandra Espíndola-Garibay,
Alberto Monroy-García,
Marta Elena Castro-Manrreza,
Guadalupe Rosario Fajardo-Orduña,
Teresa Apresa-García,
Marcos Gutiérrez-de la Barrera,
Héctor Mayani,
Juan José Montesinos
Affiliations
Víctor Adrián Cortés-Morales
Mesenchymal Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico
Luis Chávez-Sánchez
Immunology Medical Research Unit, Pediatric Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico
Leticia Rocha-Zavaleta
Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico 04510, Mexico
Sandra Espíndola-Garibay
Immunology Medical Research Unit, Pediatric Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico
Alberto Monroy-García
Immunology and Cancer Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico
Marta Elena Castro-Manrreza
Immunology and Stem Cells Laboratory, Multidisciplinary Unit of Experimental Research Zaragoza, FES, Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico
Guadalupe Rosario Fajardo-Orduña
Mesenchymal Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico
Teresa Apresa-García
Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico
Marcos Gutiérrez-de la Barrera
Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico
Héctor Mayani
Hematopoietic Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico
Juan José Montesinos
Mesenchymal Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City 06720, Mexico
Macrophages with the M2 phenotype promote tumor development through the immunosuppression of antitumor immunity. We previously demonstrated the presence of mesenchymal stem/stromal cells (MSCs) in cervical cancer (CeCa-MSCs), suggesting an immune protective capacity in tumors, but to date, their effect in modulating macrophage polarization remains unknown. In this study, we compared the capacities of MSCs from normal cervix (NCx) and CeCa to promote M2 macrophage polarization in a coculture system. Our results demonstrated that CeCa-MSCs, in contrast to NCx-MSCs, significantly decreased M1 macrophage cell surface marker expression (HLA-DR, CD80, CD86) and increased M2 macrophage expression (CD14, CD163, CD206, Arg1) in cytokine-induced CD14+ monocytes toward M1- or M2-polarized macrophages. Interestingly, compared with NCx-MSCs, in M2 macrophages generated from CeCa-MSC cocultures, we observed an increase in the percentage of phagocytic cells, in the intracellular production of IL-10 and IDO, the capacity to decrease T cell proliferation and for the generation of CD4+CD25+FoxP3+ Tregs. Importantly, this capacity to promote M2 macrophage polarization was correlated with the intracellular expression of macrophage colony-stimulating factor (M-CSF) and upregulation of IL-10 in CeCa-MSCs. Furthermore, the presence of M2 macrophages was correlated with the increased production of IL-10 and IL-1RA anti-inflammatory molecules. Our in vitro results indicate that CeCa-MSCs, in contrast to NCx-MSCs, display an increased M2-macrophage polarization potential and suggest a role of CeCa-MSCs in antitumor immunity.